期刊文献+

信号转导转录激活因子3抑制剂WP1066对肝细胞肝癌生物学特性影响的研究 被引量:1

Effects of an Inhibitor of Signal Transducer and Activator of Transcription 3,WP 1066,on the Biological Characteristics of Hepatocellular Carcinoma
下载PDF
导出
摘要 目的:探讨信号转导转录激活因子3(signal transducer and activator of transcription 3,STAT3)的抑制剂WP1066在体外对人肝细胞肝癌(hepatocellular carcinoma,HCC)增殖、侵袭能力的影响以及在体内应用时对HCC的抑制效果。方法:采用蛋白印迹、Transwell等方法检测在不同恶性潜能的人HCC细胞株中STAT3总蛋白及磷酸化水平的差异,观察应用WP1066后人HCC细胞株MHCC-97H的增殖以及侵袭能力的改变。皮下接种MHCC-97H细胞株建立裸鼠的HCC模型后,观察WP1066对肿瘤生长的影响。结果:STAT3磷酸化水平在恶性潜能高的人HCC细胞株中显著高于恶性潜能低的HCC细胞株;WP1066能显著抑制MHCC-97H的增殖和侵袭。在裸鼠HCC模型中,WP1066能有效地抑制HCC生长。结论:WP1066能抑制STAT3磷酸化水平而有效抑制HCC增殖和侵袭。 Objective:To explore the effects of an inhibitor of signal transducer and activator of transcription 3 (STAT3), WP1066, on the proliferation and invasion of hepatocellular carcinoma (HCC) cells in vitro and in vivo. Methods: The expres- sion level and phosphorylation level of STAT3 in HCC cell lines with different malignant potential were detected by Western blotting and Transwell method. The antitumor activities of WP1066 and related mechanisms were studied in HCC cell line MH- CC-97H and also in a subcutaneous HCC model in nude mice. Results: STAT3 phosphorylation level was significantly higher in HCC cell lines with higher malignant potential. WP1066 significantly inhibited cell proliferation and invasion in MHCC-97H. WP1066 also significantly inhibited the growth of tumor in nude mice HCC model. Conclusions: WP 1066 can suppress the pro- liferation and invasion of HCC through inhibition of the phosphorylation level of STAT3.
出处 《中国临床医学》 2012年第4期339-342,共4页 Chinese Journal of Clinical Medicine
基金 国家自然科学基金资助项目(编号:30872505 81172275)
关键词 肝癌 抑制剂 信号转导转录激活因子3 增殖 侵袭 Hepatocellular carcinoma Inhibitor Signal transducer and activator of transcription 3 Proliferation In-vasion
  • 相关文献

参考文献9

  • 1Chen M, Therneau T,Orsini LS,et al. Design and rationaleof the HCC BRIDGE study in China: a longitudinal? multi-center cohort trial in hepatocellular carcinoma[J]. BMC Gas-troenterol, 2011,11(5) :53. 被引量:1
  • 2Levy DE,Inghirami G. STAT3 : a multifaceted oncogene[J].Proc Natl Acad Sci USA, 2006,103(27) : 10151-10152. 被引量:1
  • 3Niu G,Wright KL,Huang M, et al. Constitutive Stat3 ac-tivity up-regulates VEGF expression and tumor angiogenesis[J]. Oncogene, 2002, 21(13):2000-2008. 被引量:1
  • 4Liu Y, Fuchs J,Li C, et al. IL-6,a risk factor for hepatocel-lular carcinoma: FLLL32 inhibits IL-6-induced STAT3 phos-phorylation in human hepatocellular cancer cells[J]. Cell Cy-cle, 2010’ 9(17):3423-3427. 被引量:1
  • 5Matsui T, Kinoshita T, Hirano T, et al. STAT3 down-regu-lates the expression of cyclin D during liver development[J].J Biol Chem, 2002,277(39):36167-36173. 被引量:1
  • 6Kesanakurti D, Chetty C, Dinh DH, et al. Role of MMP-2 inthe regulation of IL-6/Stat3 survival signaling via interactionwith alphaSbetal integrin in glioma[J]. Oncogene, 2012,29(49):6152-6160. 被引量:1
  • 7Yu H,Kortylewski M, Pardoll D. Crosstalk between cancerand immune cells: role of STAT3 in the tumour microenvi-ronment[J]. Nat Rev Immunol, 2007,7(1) :41-51. 被引量:1
  • 8Horiguchi A, Asano T, Kuroda K, et al. STAT3 inhibitorWP1066 as a novel therapeutic agent for renal cell carcinoma[J]. Br J Cancer, 2010,102( 11) : 1592-1599. 被引量:1
  • 9Hatiboglu MA, Kong LY,Wei J, et al. The tumor microen-vironment expression of p-STAT3 influences the efficacy ofcyclophosphamide with WP1066 in murine melanoma models[J]. Int J Cancer, 2011,130(7) :2812-2823. 被引量:1

同被引文献3

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部